CCL

Összesen 2 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM007778
Első szerző:Papp Mária (belgyógyász, gasztroenterológus)
Cím:New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort / Papp M., Altorjay I., Dotan N., Palatka K., Foldi I., Tumpek J., Sipka S., Udvardy M., Dinya T., Lakatos L., Kovacs A., Molnar T., Tulassay Z., Miheller P., Norman G. L., Szamosi T., Papp J., The Hungarian IBD Study Group, Lakatos P.
Dátum:2008
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
egyetemen (Magyarországon) készült közlemény
Megjelenés:The American Journal of Gastroenterology. - 103 (2008), p. 665-681. -
További szerzők:Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) Dotan, Nir Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Földi Ildikó (1981-) (orvos) Tumpek Judit (1944-) (orvosi laboratóriumi szakorvos) Sipka Sándor (1945-) (laboratóriumi szakorvos) Udvardy Miklós (1947-) (belgyógyász, haematológus) Dinya Tamás (1974-) (sebész szakorvos, onkológus szakorvos) Lakatos László (Veszprém) Kovács Ágota Molnár Tamás (orvos) Tulassay Zsolt (1944-) (belgyógyász, gasztroenterológus) Miheller Pál Norman, Gary L. Szamosi Tamás Papp János (orvos Veszprém) Lakatos Péter (Semmelweis Egyetem) The Hungarian IBD Study Group
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

2.

001-es BibID:BIBFORM048705
035-os BibID:PMID:24145678
Első szerző:Reinisch, Walter
Cím:A Randomized, Open-Label, Non-Inferiority Study of Intravenous Iron Isomaltoside 1,000 (Monofer) Compared With Oral Iron for Treatment of Anemia in IBD (PROCEED) / Walter Reinisch, Michael Staun, Rakesh K. Tandon, Istvan Altorjay, Andrew V. Thillainayagam, Cornelia Gratzer, Sandeep Nijhawan, Lars L. Thomsen
Dátum:2013
Megjegyzések:OBJECTIVES:In the largest head-to-head comparison between an oral and an intravenous (IV) iron compound in patients with inflammatory bowel disease (IBD) so far, we strived to determine whether IV iron isomaltoside 1,000 is non-inferior to oral iron sulfate in the treatment of iron deficiency anemia (IDA).METHODS:This prospective, randomized, comparative, open-label, non-inferiority study was conducted at 36 sites in Europe and India. Patients with known intolerance to oral iron were excluded. A total of 338 IBD patients in clinical remission or with mild disease, a hemoglobin (Hb) <12 g/dl, and a transferrin saturation (TSAT) <20% were randomized 2:1 to receive either IV iron isomaltoside 1,000 according to the Ganzoni formula (225 patients) or oral iron sulfate 200 mg daily (equivalent to 200 mg elemental iron; 113 patients). An interactive web response system method was used to randomize the eligible patient to the treatment groups. The primary end point was change in Hb from baseline to week 8. Iron isomaltoside 1,000 and iron sulfate was compared by a non-inferiority assessment with a margin of -0.5 g/dl. The secondary end points, which tested for superiority, included change in Hb from baseline to weeks 2 and 4, change in s-ferritin, and TSAT to week 8, number of patients who discontinued study because of lack of response or intolerance of investigational drugs, change in total quality of life (QoL) score to weeks 4 and 8, and safety. Exploratory analyses included a responder analysis (proportion of patients with an increase in Hb 2g/dl after 8 weeks), the effect of regional differences and total iron dose level, and other potential predictors of the treatment response.RESULTS:Non-inferiority in change of Hb to week 8 could not be demonstrated. There was a trend for oral iron sulfate being more effective in increasing Hb than iron isomaltoside 1,000. The estimated treatment effect was -0.37 (95% confidence interval (CI): -0.80, 0.06) with P=0.09 in the full analysis set (N=327) and -0.45 (95% CI: -0.88, -0.03) with P=0.04 in the per protocol analysis set (N=299). In patients treated with IV iron isomaltoside 1,000, the mean change in s-ferritin concentration was higher with an estimated treatment effect of 48.7 (95% CI: 18.6, 78.8) with P=0.002, whereas the mean change in TSAT was lower with an estimated treatment effect of -4.4 (95% CI: -7.4, -1.4) with P=0.005, compared with patients treated with oral iron. No differences in changes of QoL were observed. The safety profile was similar between the groups. The proportion of responders with Hb 2 g/dl (IV group: 67%; oral group: 61%) were comparable between the groups (P=0.32). Iron isomaltoside 1,000 was more efficacious with higher cumulative doses of >1,000 mg IV. Significant predictors of Hb response to IV iron treatment were baseline Hb and C-reactive protein (CRP).CONCLUSIONS:We could not demonstrate non-inferiority of IV iron isomaltoside 1,000 compared with oral iron in this study. Based on the dose-response relationship observed with the IV iron compound, we suggest that the true iron demand of IV iron was underestimated by the Ganzoni formula in our study. Alternative calculations including Hb and CRP should be explored to gauge iron stores in patients with IBD.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:American Journal of Gastroenterology. - 108 : 12 (2013), p. 1877-1888. -
További szerzők:Staun, Michael Tandon, Rakesh K. Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) Thillainayagam, Andrew V. Gratzer, Cornelia Nijhawan, Sandeep Thomsen, Lars L.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1